The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Effects of Metformin Therapy on Coronary Endothelial Dysfunction in Patients With Prediabetes With Stable Angina and Nonobstructive Coronary Artery Stenosis: The CODYCE Multicenter Prospective Study
Abstract
OBJECTIVE: To evaluate the effect of metformin therapy on coronary endothelial function and major adverse cardiac events (MACE) in patients with prediabetes with stable angina and nonobstructive coronary stenosis (NOCS). RESEARCH DESIGN AND METHODS: Metformin therapy may be needed to reduce coronary heart disease risk in patients with prediabetes. A total of 258 propensity score–matched (PSM) patients with stable angina undergoing coronary angiography were enrolled in the study. Data from 86 PSM subjects with normoglycemia (NG), 86 PSM subjects with prediabetes (pre-DM), and 86 PSM subjects with prediabetes treated with metformin (pre-DM metformin) were analyzed. During coronary angiography, NOCS was categorized by luminal stenosis <40% and fractional flow reserve >0.80. In addition, we assessed the endothelial function, measuring coronary artery diameter of left anterior descending coronary (LAD) at baseline and after the infusion of acetylcholine, by means of an intracoronary Doppler guide wire. MACE, as cardiac death, myocardial infarction, and heart failure, was evaluated at 24 months of follow-up. RESULTS: At baseline, NG patients had a lower percentage of LAD endothelial dysfunction compared with pre-DM patients (P < 0.05). The pre-DM patients had a higher percentage of endothelial LAD dysfunction as compared with the pre-DM metformin patients (P < 0.05). At the 24th month of follow-up, MACE was higher in pre-DM versus NG (P < 0.05). In pre-DM metformin patients, MACE was lower compared with pre-DM patients (P < 0.05). CONCLUSIONS: Metformin therapy may reduce the high risk of cardiovascular events in pre-DM patients by reducing coronary endothelial dysfunction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Prediabetes: a high-risk state for diabetes development
Tabák, A. G., Herder, C., Rathmann, W., Brunner, E. J., & Kivimäki, M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60283-9 · Cited by 2,958
Inoguchi, T., Li, P., Umeda, F., Yu, H. Y., Kakimoto, M., Imamura, M., Aoki, T., Etoh, T., Hashimoto, T., Naruse, M., et al. (2000) · Diabetes · doi:10.2337/diabetes.49.11.1939 · Cited by 1,577
Dresner, A., Laurent, D., Marcucci, M., Griffin, M. E., Dufour, S., Cline, G. W., Slezak, L. A., Andersen, D. K., Hundal, R. S., Rothman, D. L., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5001 · Cited by 1,311
Griffin, M. E., Marcucci, M. J., Cline, G. W., Bell, K., Barucci, N., Lee, D., Goodyear, L. J., Kraegen, E. W., White, M. F., & Shulman, G. I. (1999) · Diabetes · doi:10.2337/diabetes.48.6.1270 · Cited by 1,267
Schmidt, A. M., Hori, O., Chen, J. X., Li, J. F., Crandall, J., Zhang, J., Cao, R., Yan, S. D., Brett, J., & Stern, D. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118175 · Cited by 896 · cited 1×
“However, several previous metaanalyses have led to conflicting conclusions (3,9,10), due to differences in end point assessments and study inclusion criteria.”
ResultCachectin/TNF and IL-1 Induced by Glucose-Modified Proteins: Role in Normal Tissue Remodeling
Vlassara, H., Brownlee, M., Manogue, K. R., Dinarello, C. A., & Pasagian, A. (1988) · Science · doi:10.1126/science.3259727 · Cited by 597 · cited 1×
“However, several previous metaanalyses have led to conflicting conclusions (3,9,10), due to differences in end point assessments and study inclusion criteria.”
ResultIntroduction: Standards of Medical Care in Diabetes—2018
(2018) · Diabetes Care · doi:10.2337/dc18-sint01 · Cited by 472
Inoguchi, T., Sonta, T., Tsubouchi, H., Etoh, T., Kakimoto, M., Sonoda, N., Sato, N., Sekiguchi, N., Kobayashi, K., Sumimoto, H., et al. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000077407.90309.65 · Cited by 435
Metformin Use in Prediabetes Among U.S. Adults, 2005–2012
Tseng, E., Yeh, H.-C., & Maruthur, N. M. (2017) · Diabetes Care · doi:10.2337/dc16-1509 · Cited by 72 · cited 1×
“Although ADA guidelines suggest that patients with prediabetes be treated with metformin to reduce the risk of developing diabetes (16), to date metformin use is ,1% among adults with prediabetes and only slightly more common among those with additional risk factors for diabetes (29).”
Background
Cited by
Medina-Leyte, D. J., Zepeda-García, O., Domínguez-Pérez, M., González-Garrido, A., Villarreal-Molina, T., & Jacobo-Albavera, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083850 · Cited by 623
Hypertension-induced cognitive impairment: From pathophysiology to public health
Ungvari, Z., Toth, P., Tarantini, S., Prodan, C. I., Sorond, F., Merkely, B., & Csiszar, A. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00430-6 · Cited by 544
Mechanisms of Vascular Aging, A Geroscience Perspective
Ungvari, Z., Tarantini, S., Sorond, F., Merkely, B., & Csiszar, A. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.061 · Cited by 328
Can Metformin Exert as an Active Drug on Endothelial Dysfunction in Diabetic Subjects
Salvatore, T., Pafundi, P. C., Galiero, R., Rinaldi, L., Caturano, A., Vetrano, E., Aprea, C., Albanese, G., Di Martino, A., Ricozzi, C., et al. (2020) · Biomedicines · doi:10.3390/biomedicines9010003 · Cited by 97
Self-citation
Metadata
- Authors
- Sardu, C., Paolisso, P., Sacra, C., Mauro, C., Minicucci, F., Portoghese, M., Rizzo, M. R., Barbieri, M., Sasso, F. C., D’Onofrio, N., Balestrieri, M. L., Calabrò, P., Paolisso, G., & Marfella, R.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-02-22
- Volume
- 42
- Issue
- 10
- Pages
- 1946-1955
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2916248238
- Cited by
- 166
- References
- 10
- FWCI
- 16.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.